Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors

PURPOSE: To determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population. MATERIALS AND METHODS: Patients who were 1 to 30 years of age with relapsed/refractory solid tumors (i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Vo, Kieuhoa T., Karski, Erin E., Nasholm, Nicole M., Allen, Shelly, Hollinger, Fabienne, Clay Gustafson, W., Long-Boyle, Janel R., Shiboski, Stephen, Matthay, Katherine K., DuBois, Steven G.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5410349/
https://ncbi.nlm.nih.gov/pubmed/27793021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12904
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars